Healthcare Industry News: Abbott Vascular
News Release - August 9, 2007
Abbott Vascular Launches Crossroads Institute in JapanFacility Will Expand Physician Access to Minimally Invasive Treatment Intended to Improve Care of Patients with Vascular Disease in Asia
TOKYO, Aug. 10 (HSMN NewsFeed) -- Abbott Vascular Japan Co. Ltd. today announced the opening of the Crossroads Institute, a facility designed by Abbott to provide physicians in Asia with access to the latest advanced minimally invasive cardiac and vascular treatments and to improve the care of patients with vascular disease.
The population in Japan is rapidly aging, and the incidence of vascular disease in Asian countries is increasing. Under these circumstances, access to less invasive non-surgical treatments of vascular disease is becoming more important. Furthermore surgery can pose risks for elderly patients who may be at high risk for developing side effects from general anesthesia.
The Crossroads Institute includes more than 100 worldwide expert advisors in minimally invasive vascular treatment dedicated to improving patient care. These experts teach more than 70 courses on cardiac and vascular treatment, 50 of which are medical education (CME) accredited. The courses are designed and moderated by experts using high-touch teaching methods, including 2-dimensional virtual simulators and a virtual in-house catheterization lab complete with a model of the human body. The Crossroads Institute also features live-case broadcasts from neighboring hospitals, to bring real-time catheterization lab events into forums for discussion, which are then moderated by the experts.
"Abbott Vascular Japan is dedicated to improving the treatment of cardiac and vascular disease by providing physicians in Asia with access to the latest minimally invasive treatment techniques, devices, and practical hands-on education," said Geoffrey Hasemer, president, Abbott Vascular Japan. "By expanding access to leading-edge treatment, we aim to positively impact the treatment of cardiac and vascular disease in Japan and Asia."
Headquartered in Brussels, Belgium, and with established facilities in Johannesburg, South Africa, as well as Tokyo, the Crossroads Institute (formerly the Guidant Institute for Therapy Advancement) was first introduced in Japan in 2003 as a pioneering effort in Asia to expand physician access to the latest minimally invasive vascular disease treatment strategies to improve patient care.
About the Crossroads Institute
Providing leadership in interventional medical education since 2000, the Crossroads Institute was the first medical learning institute of its kind established in the world to advance the open exchange of information about cardiac and vascular care in order to help healthcare professionals improve the treatment of patients with cardiac and vascular disease. Since its establishment, the Crossroads Institute has provided education to over 600 medical professionals around the world. The Crossroads Institute is a world class medical education facility funded by Abbott and headquartered in Brussels, Belgium with offices in Johannesburg, South Africa and Tokyo, Japan. For more information about The Crossroads Institute, phone +32-2-714-14-65 or visit http://www.crossroads-institute.com.
About Abbott Vascular
Abbott Vascular, a division of Abbott, is one of the world's leading vascular care businesses. Abbott Vascular is uniquely focused on advancing the treatment of vascular disease and improving patient care by combining the latest medical device innovations with world-class pharmaceuticals, investing in research and development, and advancing medicine through training and education. Headquartered in Northern California, Abbott Vascular offers a comprehensive portfolio of vessel closure, endovascular and coronary products that are recognized internationally for their safety and effectiveness in treating patients with vascular disease.
Abbott (NYSE: ABT ) is a global, broad-based health care company devoted to the discovery, development, manufacture and marketing of pharmaceuticals and medical products, including nutritionals, devices and diagnostics. The company employs 65,000 people and markets its products in more than 130 countries.
Abbott's news releases and other information are available on the company's Web site at http://www.abbott.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.
Related News ItemsAbbott Receives FDA Emergency Use Authorization for COVID-19 Antibody Blood Test on Alinity(TM) i System
Abbott's TriClip(TM) Becomes First Device of its Kind to Receive CE Mark for Minimally Invasive Tricuspid Valve Repair
Abbott Aims to Optimize TAVI Implants with European Approval of FlexNav(TM) Delivery System for the Company's Portico(TM) Valve